Aliases:This biomarker is also known as:
- integrin beta-1,
- Fibronectin receptor subunit beta,
- VLA-4 subunit beta,
- integrin VLA-4 beta subunit,
- CD29 antigen,
- integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12),
- very late activation protein, beta polypeptide,
ITGB1 is a beta subunit of the heterodimeric integrin protein. Integrins are ubiquitously expressed adhesion molecules composed of alpha and beta subunits. In mammals, 18 alpha and 8 beta subunits have been identified. Integrin family members are membrane receptors involved in cell adhesion and recognition in a variety of processes including embryogenesis, hemostasis, tissue repair, immune response and metastatic diffusion of tumor cells. Several protein isoforms have been identifed, arising from alternatively spliced transcript variants.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
ITGB1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.